Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
TransCode Therapeutics, Inc. logo — Delivering a cancer-free future

TransCode Therapeutics, Inc.

Delivering a cancer-free future

Founded 2016 United States Newton, United States 11 employees Post Ipo Equity Total: $28.05M Biotechnology, Health Care +1

General Information

Company Name TransCode Therapeutics, Inc.
Founded Year 2016
Location United States Newton, United States +1
Employees 11
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when TransCode Therapeutics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a biotechnology startup founded in 2016, with a mission to deliver a cancer-free future for all cancer patients. The company focuses on the intelligent design and efficient delivery of targeted therapeutics, particularly TTX-MC138, which targets microRNA-10b, considered the master regulator of metastatic cell viability in various cancers. Additionally, TransCode has preclinical programs such as TTX-siPDL1 and TTX-siLIN28B for solid tumor treatment, and cancer agnostic programs including TTX-RIGA, TTX-CRISPR, and TTX-mRNA. The company has recently received a $7.25M Post-IPO Equity investment on 18 January 2024, indicating investor confidence in its potential. TransCode's proprietary delivery platform, TTX, enables the transport of targeted therapeutics to cancer cells, offering a solution to the challenge of delivery in cancer therapy. With a rapidly expanding platform of drug candidates and a world-class team, TransCode aims to target a variety of tumor indications with the goal of long-term treatment survival. The company's focus on addressing the highest unmet need in cancer treatment makes it an intriguing prospect for investors in the health care and biotechnology industries.

Taxonomy: cancer therapeutics, targeted therapies, biomarker targeting, RNA-based therapies, gene therapy, oncology research, drug delivery technology, microRNA-10b, PD-L1 modulation, CRISPR/Cas9, cancer vaccine development, tumor microenvironment, cancer treatment innovation, precision medicine, immunotherapy

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 22 Jul 2024
Post-IPO Equity •••••• - 18 Jan 2024
Post-IPO Equity •••••• - 30 Nov 2023
Post-IPO Equity •••••• - 26 Oct 2023
Post-IPO Equity •••••• - 25 Sep 2023

View All 10 Funding Rounds

TransCode Therapeutics, Inc. Alternatives & Competitors

TransCode Therapeutics, Inc. vs
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. United States

Developing next-generation targeted combination therapies to advance the care of cancer patients.

Series A
39 employees
Compare TransCode Therapeutics, Inc. vs Convergent Therapeutics, Inc.
TransCode Therapeutics, Inc. vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post Ipo Equity
157 employees
Biotechnology, Health Care
TransCode Therapeutics, Inc. vs
Ligandal
Ligandal United States

Ligandal is developing precision molecular therapeutics and targeted delivery technologies.

Seed
12 employees
Biotechnology

FAQ About TransCode Therapeutics, Inc.

Delivering a cancer-free future
TransCode Therapeutics, Inc. was founded in 2016.
TransCode Therapeutics, Inc. is headquartered in Newton, United States.
TransCode Therapeutics, Inc. operates in the following industries: Biotechnology, Health Care, Health and Wellness.
TransCode Therapeutics, Inc. has approximately 11 employees.
TransCode Therapeutics, Inc. has completed 10 funding rounds, raising a total of $28.05M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to TransCode Therapeutics, Inc. include Convergent Therapeutics, Inc., Tango Therapeutics, Ligandal, Stipple Bio, SIRNAOMICS. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TransCode Therapeutics, Inc. and Convergent Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TransCode Therapeutics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy